Aiforia Technologies
3.66
EUR
0 %
AIFORIA
First North Finland
Medical Equipment & Services
Health Care
1,704 following
0%
-14.69%
-20.26%
-7.34%
+4.87%
-5.18%
-
-
-27.67%
investors.aiforia.com
Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of areas from oncology to neuroscience. Aiforia Technologies is headquartered in Finland.
P/E (adj.) (24e)
-8.8
EV/EBIT (adj.) (24e)
-8.29
P/B (24e)
6.74
Dividend yield-% (24e)
-
Target price
4.60 EUR
Recommendation
Accumulate
Updated
2.10.2024
First North Finland
AIFORIA
Daily low / high price
3.59 / 3.73
EUR
Market cap
105.83M EUR
Turnover
38.01K EUR
Volume
10K
Business risk
Valuation risk
Current
Previous
Latest research
Extensive report
Inderes' extensive report is an investor's handbook on customer companies covered by our research.
The latest extensive report was released
Read the reportAnalyst
Antti Luiro
Head of Nordic ER Development, Analyst
Frans-Mikael Rostedt
Analyst
Latest videos
Financial calendar
Annual report
07.03.2025
General meeting
04.04.2025
Interim report
28.08.2025
Income statement
| 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.8 | 1.0 | 1.6 | 2.4 | 3.4 | 5.8 | 9.9 | 17.1 |
| growth-% | 32.9 % | 14.7 % | 64.9 % | 49.3 % | 41.2 % | 71.1 % | 71.1 % | 72.4 % |
| EBITDA | -1.6 | -3.5 | -9.5 | -9.7 | -8.2 | -7.0 | -3.7 | 2.5 |
| EBIT (adj.) | -2.6 | -4.7 | -11.8 | -12.9 | -12.1 | -11.8 | -9.9 | -3.9 |
| EBIT | -2.6 | -4.7 | -11.8 | -12.9 | -12.1 | -11.8 | -9.9 | -3.9 |
| Profit before taxes | -2.8 | -7.6 | -12.2 | -12.9 | -12.0 | -11.9 | -10.2 | -4.2 |
| Net income | -2.8 | -7.6 | -12.2 | -12.9 | -12.0 | -11.9 | -10.2 | -4.2 |
| EPS (adj.) | -0.14 | -0.29 | -0.47 | -0.50 | -0.42 | -0.41 | -0.35 | -0.15 |
| growth-% | ||||||||
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio |
Profitability and return on capital
| 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
|---|---|---|---|---|---|---|---|---|
| EBITDA-% | -189.8 % | -354.2 % | -593.3 % | -404.5 % | -241.9 % | -120.5 % | -36.9 % | 14.6 % |
| EBIT-% (adj.) | -310.1 % | -481.4 % | -731.9 % | -537.1 % | -358.4 % | -204.4 % | -100.0 % | -22.9 % |
| EBIT-% | -310.1 % | -481.4 % | -731.9 % | -537.1 % | -358.4 % | -204.4 % | -100.0 % | -22.9 % |
| ROE | -386.3 % | -39.0 % | -36.2 % | -54.8 % | -71.4 % | -123.5 % | 724.2 % | 48.9 % |
| ROI | -77.0 % | -20.9 % | -31.8 % | -45.4 % | -51.3 % | -56.0 % | -54.6 % | -23.0 % |
Valuation
| 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
|---|---|---|---|---|---|---|---|---|
| Share price (EUR) | 5.01 | 5.22 | 3.23 | 3.49 | 3.66 | 3.66 | 3.66 | 3.66 |
| Shares | 20.0 | 25.8 | 25.8 | 26.0 | 28.8 | 28.8 | 28.8 | 28.9 |
| Market cap | 100.1 | 134.6 | 83.4 | 90.6 | 105.4 | 105.4 | 105.5 | 105.7 |
| Enterprise value | 101.4 | 99.4 | 62.4 | 82.4 | 100.5 | 112.4 | 121.6 | 125.0 |
| EV/S | 119.4 | 102.0 | 38.9 | 34.4 | 29.7 | 19.4 | 12.3 | 7.3 |
| EV/EBITDA | - | - | - | - | - | - | - | 50.2 |
| EV/EBIT (adj.) | - | - | - | - | - | - | - | - |
| EV/EBIT | - | - | - | - | - | - | - | - |
| P/E (adj.) | - | - | - | - | - | - | - | - |
| P/E | - | - | - | - | - | - | - | - |
| P/B | 112.9 | 3.5 | 2.8 | 5.1 | 6.7 | 28.5 | - | - |
| P/S | 117.9 | 138.2 | 51.9 | 37.8 | 31.1 | 18.2 | 10.7 | 6.2 |
| Dividend yield | ||||||||
| Equity ratio | 16.8 % | 86.4 % | 80.3 % | 63.5 % | 55.0 % | 15.0 % | -26.6 % | -41.9 % |
| Gearing ratio | 146.0 % | -92.8 % | -71.6 % | -45.4 % | -31.1 % | 191.1 % | -246.5 % | -179.5 % |
Quarter data
| Q3/23 | Q4/23 | 2023 | Q1/24 | Q2/24 | Q3/24e | Q4/24e | 2024e | Q1/25e | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.4 | 2.4 | 1.4 | 2.0 | 3.4 | ||||
| EBITDA | -4.7 | -9.7 | -4.2 | -4.0 | -8.2 | ||||
| EBIT | -6.5 | -12.9 | -6.1 | -6.1 | -12.1 | ||||
| Profit before taxes | -6.4 | -12.9 | -6.0 | -6.0 | -12.0 | ||||
| Net income | -6.4 | -12.9 | -6.0 | -6.0 | -12.0 |
ShowingAll content types
Aiforia enters into new partnership to offer competitor's image analysis models on its own platform
Aiforia and Paige form strategic partnership to advance AI integration in pathology laboratories
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools